Human CAM ELISA Kit (DEIA3251)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
plasma, serum
Species Reactivity
Human
Intended Use
Human CAM ELISA Kit is a sandwich enzyme immunoassay for the quantitative measurement of human CAM (calmodulin).
Contents of Kit
1. Assay plate
2. Standard
3. Sample Diluent
4. Assay Diluent A
5. Assay Diluent B
6. Detection Reagent A
7. Detection Reagent B
8. Wash Buffer (25X)
9. Substrate
10. Stop Solution
Storage
Store the unopened kit at 4°C upon receipt and when it is not in use. For more detailed information, please download the following document on our website.

Citations


Have you cited DEIA3251 in a publication? Let us know and earn a reward for your research.

Related Products


Calmodulin ELISA Kit (DEIA-XYA323)

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Dominant Negative MCP-1 Blocks Human Osteoclast Differentiation

JOURNAL OF CELLULAR BIOCHEMISTRY

Authors: Morrison, Nigel A.; Day, Christopher J.; Nicholson, Geoff C.

Human osteoclasts were differentiated using receptor activator of NFB ligand (RANKL) and macrophage colony stimulating factor (M-CSF) from colony forming unit-granulocyte macrophage (CFU-GM) precursors of the myeloid lineage grown from umbilical cord blood. Gene expression profiling using quantitative polymerase chain reaction (Q-PCR) showed more than 1,000-fold induction of chemokine MCP-1 within 24h of RANKL treatment. MCP-1 mRNA content exceeds that of other assayed chemokines (CCL1, 3, 4, and 5) at all time points up to day 14 of treatment. MCP-1 induction preceded peak induction of calcium signaling activator calmodulin 1 (CALM1) and transcription factors JUN and FOS, which were at 3 days. Key osteoclast related transcription factors NFATc1 and NFATc2 showed peak induction at 7 days, while marker genes for osteoclast function cathepsin K and tartrate resistance acid phosphatase (TRAP) were maximally induced at 14 days, corresponding with mature osteoclast function. To test whether the early and substantial peak in MCP-1 expression is part of human osteoclast differentiation events, a dominant negative inhibitor of MCP-1 (7ND) was added simultaneously with RANKL and M-CSF, resulting in blockade of CALM1, JUN and NFATc2 induction and strong inhibition of human osteoclast differentiation. These data show that a cascade of gene expression leading to osteoclast differentiation depends on intact early MCP-1 induction and signaling in human osteoclasts. J. Cell. Biochem. 115: 303-312, 2014. (c) 2013 Wiley Periodicals, Inc.

The significance of low plasma miR-335 level in patients with acute cerebral infarction may be associated with the loss of control of CALM1 expression

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE

Authors: Yuan, Mei; Yuan, Haijun; Zhou, Chengfang; Liu, Feng; Lin, Chen; Tang, Yonghong

Calcium overload, mediated by calmodulin (CaM), plays an important role in ischemia/reperfusion injury during acute ischemic brain damage. However, the regulation of CaM expression in cerebral ischemia is still not fully addressed. This study showed that the levels of plasma miR-335 were significantly down-regulated in 152 patients with acute cerebral infarction (0.60 +/- 0.31) compared to 136 age-matched healthy controls (1.16 +/- 0.30) (P < 0.01). Moreover, the levels negatively correlated with the National Institutes of Health Stroke Scale (NIHSS) scores in acute cerebral infarction patients (r = -0.680; P < 0.01). Transfection of miR-335 mimics and inhibitors inhibited CALM1 mRNA and CaM protein expressions in HUVECs. This study suggests that miR-335 is an important biomarker of acute cerebral infarction, and which functions are through regulating the expression of the CALM1 gene during acute ischemic brain injury. Our findings highlighted the potential of miR-335 as a target to develop agents to treat acute cerebral infarction.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket